C4 Therapeutics adds Glenn Dubin to its Board of Directors

– USA, MA –  C4 Therapeutics, Inc., today announced the addition of Glenn Dubin to the Company’s Board of Directors. Mr. Dubin is the Principal of Dubin & Co. LP, a private investment company based in New York. He brings three decades of experience leading global, multi-strategy organizations across a wide range of industries to C4T’s Board.

“I am delighted to have Glenn join our Board,” said Andy Phillips, President and Chief Executive Officer of C4T. “Glenn’s unique background will offer valuable business and financial insights to our executive leadership as we continue to advance molecules discovered and refined by our Daedalus platform toward new therapies for patients with serious disease.”

Marc Cohen, C4T’s Executive Chairman, added, “Glenn’s broad leadership experience across a wide variety of industries will be tremendously valuable as we continue to grow C4T as a leader in medicines based on targeted protein degradation.”

About Glenn Dubin

Mr. Dubin co-founded Highbridge Capital Management LLC, an alternative asset management company in 1992. In 2009, Highbridge was acquired by JP Morgan Asset Management, and Mr. Dubin remained at the helm to oversee the transition. In 2012, Mr. Dubin, along with a prominent group of investors, acquired Castleton Commodities International LLC, a global merchant energy company active in the physical and financial commodity markets and infrastructure investing. In 2013, Mr. Dubin stepped down as Chairman and CEO of Highbridge to focus on Dubin & Co. and the founding of Engineers Gate LP, a proprietary quantitative trading company. Engineers Gate has committed itself to building a next generation operating and technology platform for systematic trading strategies across global liquid markets.

“C4T is an exciting company pioneering a new approach to attacking disease by harnessing the innate machinery of the cell to eliminate disease-causing proteins. I am looking forward to helping the company maintain the remarkable momentum they have toward clinical studies with multiple degraders,” said Mr. Dubin.

Mr. Dubin is a founding Board member and former Board Chair of The Robin Hood Foundation. He is also a trustee of Mount Sinai Medical Center in New York, a Board member of the Museum of Modern Art, and is a member of the Dean’s Executive Committee of the Harvard Kennedy School. Mr. Dubin holds a B.A. in economics from the State University of New York at Stony Brook.

About C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively target disease-relevant proteins for degradation using the innate machinery of the cell. This targeted protein degradation approach has the potential to treat a range of diseases and offers advantages over traditional drugs, such as potential to minimize drug resistance, de-risked starting points, high potency and specificity.

For more information : https://c4therapeutics.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.